Your browser doesn't support javascript.
loading
Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations.
Freedman, Mark S; Devonshire, Virginia; Duquette, Pierre; Giacomini, Paul S; Giuliani, Fabrizio; Levin, Michael C; Montalban, Xavier; Morrow, Sarah A; Oh, Jiwon; Rotstein, Dalia; Yeh, E Ann.
Afiliação
  • Freedman MS; The University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
  • Devonshire V; University of British Columbia, Vancouver, British Columbia, Canada.
  • Duquette P; Centre hospitalier de l'Université de Montréal, Montreal, Québec, Canada.
  • Giacomini PS; Montreal Neurological Institute and Hospital, Montreal, Québec, Canada.
  • Giuliani F; University of Alberta, Edmonton, Alberta, Canada.
  • Levin MC; University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
  • Montalban X; St. Michael's Hospital, Toronto, Ontario, Canada.
  • Morrow SA; London Health Sciences Centre, London, Ontario, Canada.
  • Oh J; St. Michael's Hospital, Toronto, Ontario, Canada.
  • Rotstein D; St. Michael's Hospital, Toronto, Ontario, Canada.
  • Yeh EA; The Hospital for Sick Children, Toronto, Ontario, Canada.
Can J Neurol Sci ; 47(4): 437-455, 2020 07.
Article em En | MEDLINE | ID: mdl-32654681
ABSTRACT
The Canadian Multiple Sclerosis Working Group has updated its treatment optimization recommendations (TORs) on the optimal use of disease-modifying therapies for patients with all forms of multiple sclerosis (MS). Recommendations provide guidance on initiating effective treatment early in the course of disease, monitoring response to therapy, and modifying or switching therapies to optimize disease control. The current TORs also address the treatment of pediatric MS, progressive MS and the identification and treatment of aggressive forms of the disease. Newer therapies offer improved efficacy, but also have potential safety concerns that must be adequately balanced, notably when treatment sequencing is considered. There are added discussions regarding the management of pregnancy, the future potential of biomarkers and consideration as to when it may be prudent to stop therapy. These TORs are meant to be used and interpreted by all neurologists with a special interest in the management of MS.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Guias de Prática Clínica como Assunto / Esclerose Múltipla Tipo de estudo: Guideline / Prognostic_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Can J Neurol Sci Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Guias de Prática Clínica como Assunto / Esclerose Múltipla Tipo de estudo: Guideline / Prognostic_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Can J Neurol Sci Ano de publicação: 2020 Tipo de documento: Article